79 related articles for article (PubMed ID: 12941812)
1. Measurement of genomic instability in preleukemic P190BCR/ABL transgenic mice using inter-simple sequence repeat polymerase chain reaction.
Brain JM; Goodyer N; Laneuville P
Cancer Res; 2003 Aug; 63(16):4895-8. PubMed ID: 12941812
[TBL] [Abstract][Full Text] [Related]
2. The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice.
Brain J; Saksena A; Laneuville P
Leuk Res; 2002 Nov; 26(11):1011-6. PubMed ID: 12363470
[TBL] [Abstract][Full Text] [Related]
3. Cytogenetic characterization of a BCR-ABL transduced mouse cell line.
Rudolph C; Hegazy AN; von Neuhoff N; Steinemann D; Schröck E; Stripecke R; Klein C; Schlegelberger B
Cancer Genet Cytogenet; 2005 Aug; 161(1):51-6. PubMed ID: 16080957
[TBL] [Abstract][Full Text] [Related]
4. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias.
Shah NP; Sawyers CL
Oncogene; 2003 Oct; 22(47):7389-95. PubMed ID: 14576846
[TBL] [Abstract][Full Text] [Related]
6. Mutator phenotype of BCR--ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta.
Canitrot Y; Lautier D; Laurent G; Fréchet M; Ahmed A; Turhan AG; Salles B; Cazaux C; Hoffmann JS
Oncogene; 1999 Apr; 18(17):2676-80. PubMed ID: 10348341
[TBL] [Abstract][Full Text] [Related]
7. BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.
Hemmeryckx B; Reichert A; Watanabe M; Kaartinen V; de Jong R; Pattengale PK; Groffen J; Heisterkamp N
Oncogene; 2002 May; 21(20):3225-31. PubMed ID: 12082638
[TBL] [Abstract][Full Text] [Related]
8. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
9. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
Pienkowska-Grela B; Woroniecka R; Solarska I; Kos K; Pastwińska A; Konopka L; Majewski M
Cancer Genet Cytogenet; 2007 Apr; 174(2):111-5. PubMed ID: 17452251
[TBL] [Abstract][Full Text] [Related]
10. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
[TBL] [Abstract][Full Text] [Related]
11. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
Mishra S; Zhang B; Cunnick JM; Heisterkamp N; Groffen J
Cancer Res; 2006 May; 66(10):5387-93. PubMed ID: 16707466
[TBL] [Abstract][Full Text] [Related]
12. Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice.
Hemmeryckx B; van Wijk A; Reichert A; Kaartinen V; de Jong R; Pattengale PK; Gonzalez-Gomez I; Groffen J; Heisterkamp N
Cancer Res; 2001 Feb; 61(4):1398-405. PubMed ID: 11245441
[TBL] [Abstract][Full Text] [Related]
13. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
Wang Z; Sampath J; Fukuda S; Pelus LM
Cancer Res; 2005 Sep; 65(18):8224-32. PubMed ID: 16166298
[TBL] [Abstract][Full Text] [Related]
14. BCR-ABL in chronic myelogenous leukemia--how does it work?
Goldman JM; Melo JV
Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.
Pytel D; Wysocki T; Majsterek I
Comp Biochem Physiol C Toxicol Pharmacol; 2006 Sep; 144(1):85-92. PubMed ID: 16904383
[TBL] [Abstract][Full Text] [Related]
16. Influence of BCR/ABL fusion proteins on the course of Ph leukemias.
Telegeev GD; Dubrovska AN; Dybkov MV; Maliuta SS
Acta Biochim Pol; 2004; 51(3):845-9. PubMed ID: 15448745
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines.
van der Kuip H; Moehring A; Wohlbold L; Miething C; Duyster J; Aulitzky WE
Leuk Res; 2004 Apr; 28(4):405-8. PubMed ID: 15109541
[TBL] [Abstract][Full Text] [Related]
18. STI571 reduces NER activity in BCR/ABL-expressing cells.
Sliwinski T; Czechowska A; Szemraj J; Morawiec Z; Skorski T; Blasiak J
Mutat Res; 2008 Jul; 654(2):162-7. PubMed ID: 18602021
[TBL] [Abstract][Full Text] [Related]
19. Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice.
Mizuno T; Yamasaki N; Miyazaki K; Tazaki T; Koller R; Oda H; Honda ZI; Ochi M; Wolff L; Honda H
Oncogene; 2008 May; 27(24):3465-74. PubMed ID: 18193087
[TBL] [Abstract][Full Text] [Related]
20. Transient pancytopenia preceding acute lymphoblastic leukemia with positive Philadelphia chromosome.
Li Q; Chen Z; You Y; Zou P
Leuk Res; 2008 Aug; 32(8):1317-20. PubMed ID: 18291524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
